Myriad Genetics, Inc. · NASDAQ:MYGN

Myriad Genetics — Q1 2025 Earnings Presentation

24 slides from Myriad Genetics's earnings presentation, May 6, 2025

  1. Slide 1: First Quarter 2025 Earnings Call

    First Quarter 2025 Earnings Call May 6, 2025 ©2025 Myriad Genetics, Inc.

  2. Slide 2: Forward-looking statements and Non-GAAP financial measures

    Forward-looking statements and Non-GAAP financial measures Some of the FORWARD-LOOKING STATEMENTS AND DISCLAIMERS information presented These statements are based on management’s current expectations and the actual events or results may differ materially and adversely here today contains from these

  3. Slide 3: First quarter 2025 financial results and 2025 Guidance

    First quarter 2025 financial results and 2025 Guidance Q1 revenue headwinds; disciplined OpEx management Updated 2025 financial guidance reflects current business outlook and Total revenue declined 3% YOY but grew 5% YOY excluding programs to improve growth the UNH GeneSight impact, EndoPredict dive

  4. Slide 4: Mark Verratti, Chief Operating Officer

    Mark Verratti CHIEF OPERATING OFFICER ©2025 Myriad Genetics, Inc. 4

  5. Slide 5: First quarter 2025 commercial highlights

    First quarter 2025 commercial highlights Q1 trends reflect: Total Revenue Prenatal RevenueHereditary Cancer • Prequel Early Gestational Age continued to gain Figures in millions $70 traction, contributing to Prenatal performance • Total Hereditary cancer testing (HCT) revenue (3)% $55 11% YOY Q1‘25

  6. Slide 6: Oncology First quarter 2025 and recent highlights

    Oncology First quarter 2025 and recent Operational results highlights Q1 ’25 Hereditary cancer testing revenue in Oncology was flat YOY due to prior period contributions; volume $78M Q1 ’25 revenue grew 5% YOY Q1 ‘25 Prolaris revenue declined 2% YOY, reflecting stability post National ~52k Comprehen

  7. Slide 7: Women's Health First quarter 2025 and recent highlights

    Women’s Health First quarter 2025 and recent Operating results highlights Q1 ’25 prenatal testing growth supported by ongoing traction of recently launched Prequel Early $87M Q1 ’25 revenue Gestational Age NIPS ~206k In January 2025, Myriad Genetics unveiled groundbreaking research relating to Prequ

  8. Slide 8: Pharmacogenomics First quarter 2025 and recent highlights

    Pharmacogenomics First quarter 2025 and recent highlights Operational results Number of providers continues to expand, now at 30,000+ and counting $31M Q1 ’25 revenue In April 2025, the Journal of Clinical Psychopharmacology published a study showing those with major ~127k Q1 ‘25 volume depressive d

  9. Slide 9: Scott Leffler, Chief Financial Officer

    Scott Leffler CHIEF FINANCIAL OFFICER ©2025 Myriad Genetics, Inc. 9

  10. Slide 10: Q1 Financial Performance

    Q1 Financial Performance All figures in millions, except per share amounts and percentages Total revenue Adjusted Gross Margin* Adjusted Operating Expense* Adjusted EPS* (3)% 50bps 1% YOY Q1‘25 YOY Q1‘25 72% YOY Q1‘25 $205 $0.05 202 $150 196 69.0% 68.5% 141 139 $185 $0.00 (0.01) (0.03) $120 $165 60%

  11. Slide 11: Better understanding of our underlying revenue growth

    Better understanding of our underlying revenue growth (Q1 ‘24 to Q1 ‘25) Total revenue* All figures in millions, except percentages $205 202 +5% For comparison YOY Q1 ‘25 $200 purposes, reported Q1 3 196 ’24 revenue included $195 3 ~$16 million from items that did not contribute in $190 Q1 ‘25 186 E

  12. Slide 12: Profitability and Liquidity

    Profitability and Liquidity Adjusted Gross Profit1 Adjusted EBITDA1 All figures in millions, except percentages Achieved (2)% Breakeven YOY Q1 ‘25 Quarter ended March 31, 2025 $140 139 Liquidity position2 Access to 135 Q1 ‘25 adj. operating $92 million cash flow1 was (cash and cash equivalents) $(10

  13. Slide 13: Updating 2025 financial guidance

    Updating 2025 financial guidance All figures in millions, except per share amounts and percentages 2025 Prior 2025 Current Adjustments to 2025 business outlook: Total revenue $840 - $860 $807 - $823 Revised PGx and HCT unaffected test volume growth • PGx: combination of lower Q1 ‘25 revenue growth f

  14. Slide 14: Strategy Team Execution

    Strategy Team Execution Reinforcing the foundation to build long-term shareholder value ©2025 Myriad Genetics, Inc. 14

  15. Slide 15: Q&A

    Q&A ©2025 Myriad Genetics, Inc. 15

  16. Slide 16: Appendix

    Appendix ©2025 Myriad Genetics, Inc. 16

  17. Slide 17: Reconciliation of GAAP to Non-GAAP – Adjusted Gross Margin

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024 – Adjusted Gross Margin (unaudited data in millions, except per share amounts) ©2025 Myriad Genetics, Inc. 17

  18. Slide 18: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024 – Adjusted Operating Expenses (unaudited data in millions) ©2025 Myriad Genetics, Inc. 18

  19. Slide 19: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024 – Adjusted Operating Expenses (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Consists of the non-cash equity-based compensation pro

  20. Slide 20: Reconciliation of GAAP to Non-GAAP – Adjusted Net Loss

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024– Adjusted Net Loss (unaudited data in millions, except per share amounts) ©2025 Myriad Genetics, Inc. 20

  21. Slide 21: Reconciliation of GAAP to Non-GAAP – Adjusted Net Loss (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024 - Adjusted Net (Loss) (Cont.) (1) To determine Adjusted Earnings (Loss) Per Share, or adjusted EPS. (2) Represents recurring amortization charges resulting from the acquisition of intangible asse

  22. Slide 22: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024– Adjusted EBITDA (unaudited data in millions) ©2025 Myriad Genetics, Inc. 22

  23. Slide 23: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA (Cont.)

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024 - Adjusted EBITDA (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Depreciation expense excludes depreciation included in real estate

  24. Slide 24: Reconciliation of GAAP to Non-GAAP – Adjusted Free Cash Flow

    Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months ended March 31, 2025 and 2024– Adjusted Free Cash Flow (unaudited data in millions) ©2025 Myriad Genetics, Inc. 24

Myriad Genetics — Q1 2025 Earnings Presentation on 6ix